

ASCORBIC ACID LOADED PLGA NANOPARTICLES
GEL AS POTENTIAL ORAL SQUAMOUS CELL
CARCINOMA SITE-SPECIFIC TREATMENT

BY

NURUL AIN BINTI MOHAMMAD HAMDI

A thesis submitted in fulfilment of the requirement for the
degree of Master of Science in Pharmacy

Kulliyyah of Pharmacy
International Islamic University Malaysia

AUGUST 2021

ABSTRACT

Oral squamous cell carcinoma (OSCC) represents the majority of oral cancer. Chemotherapy is commonly used to treat OSCC especially as the disease advanced. However, conventional chemotherapy is associated with terrible adverse effects and the occurrence of chemoresistance which causes treatment failure. Therefore, the quest for a more effective and safer alternative has intensified. High dose ascorbic acid has been evidenced to confer anticancer effects via generation of reactive oxygen species (ROS) and through epigenetic mechanisms. Poly lactic-co-glycolic acid (PLGA) was used as the encapsulating polymer for the delivery of ascorbic acid to the cancer cells. A rapid UV-visible spectrophotometric method was validated as per ICH guideline and applied throughout this study for the quantification of ascorbic acid. Double emulsion solvent evaporation method was used to fabricate ascorbic acid loaded PLGA (AA-PLGA) nanoparticles. Optimisation of formulation was carried out by multilevel categoric full factorial design based on different surfactant concentrations and surfactant types used in the primary emulsion. The particle size of the optimised formulation was found to be 252 ± 2.98 nm, polydispersity index (PDI) of 0.151 ± 0.02 , zeta potential of -20.93 ± 0.87 mV and encapsulation efficiency of $69.73 \pm 1.07\%$. Scanning electron microscope images revealed the spherical shape of nanoparticles. The drug release behaviour exhibited a biphasic pattern namely initial burst release followed by slower release. The optimised nanoparticles formulation was further incorporated into different concentrations of Carbopol[®] gel. The pH of the prepared formulations was well within the pH range of the oral cavity which is between 6.2 – 7.6. Statistical analysis indicated that Carbopol[®] concentration significantly (p -value < 0.05) affected viscosity, spreadability and mucoadhesion of the gels. The properties of the prepared formulations were compared with a Carbopol[®] based commercial product (Kin Care) as a reference. Carbopol[®] polymer with a strength of 1% was chosen as the optimum gelling agent for AA-PLGA nanoparticles gel. The viscosity of the formulation with 1% Carbopol[®] was slightly higher (p -value < 0.05) than the commercial product, yet the spreadability and adhesion results were comparable (p -value > 0.05). The rheological study showed that all the gels exhibited a pseudoplastic behaviour which is desirable as it facilitates the flow of gel out of the tube and can form a viscous gel at the application site. Besides, the optimum gel formulation exhibited a zero-order kinetic release of ascorbic acid nanoparticles for 6 hours duration. Hence, it is a good candidate for topical application on the oral mucosa. The optimised AA-PLGA nanoparticles were subjected to cytotoxic assay against the OSCC SCC-25 cell line. Through in vitro cytotoxicity study, AA-PLGA nanoparticles mediated a significant (p -value < 0.05) reduction of cancer cell viability in a dose-dependent manner with an IC_{50} value of 2420 μ g/mL. Severe cellular morphological changes were examined with an inverted microscope after 24 hours of incubation with AA-PLGA nanoparticles evidenced the cancer cell death in the SCC-25 cell line. The results of the present study support the feasibility of AA-PLGA nanoparticles gel to treat OSCC and hope the formulation can open a new avenue for OSCC therapy.

ملخص البحث

سرطان الخلايا الحرفشية الفموي (OSCC) يمثل غالبية سرطان الفم. العلاج الكيميائي التقليدي يرتبط بآثار ضارة رهيبة وظاهرة التشعب الكيميائي في سرطان الفم التي تسبب قصورا في العلاج. ولذلك، فإن الجهود قد تكثفت سعيا إلى إيجاد بديل أكثر فعالية وأمان. حمض الأسكوربيك يضيف تأثيرات مضادات للسرطان من خلال توليد أنواع الأكسجين المتفاعل (ROS) ومن خلال آليات epigenetic. استخدام حمض الجليكوليك متعدد حمض اللاكتيك (PLGA) باعتباره البوليمر المغلف للحمض الأسكوربيك لإيصاله إلى الخلايا السرطانية. وقد تم تطبيق طريقة قياس الأشعة فوق البنفسجية طوال هذه الدراسة على كمية حمض الأسكوربيك. وقد استخدمت طريقة تبخر المذيبات المزوجة لصنع أحماض الأسكوربيك المحملة بالمواد النانوية المشحونة (AA-PLGA). تم إجراء تحسين الصياغة من خلال تصميم عاملي شامل متعدد المستويات يعتمد على تركيزات معاملات التوتر السطحي المختلفة وأنواعها المستخدمة في المستحلب الأولي. حجم الجسيمات في الصيغة المثلى هو 2.98 ± 252 نانومتر، ومؤشر تعدد الجسيمات (PDI) من 0.02 ± 0.151 ، وإمكانية زيتا من -20.93 ± 0.87 ميغا إلكترون فولت، وكفاءة التغليف $69.73 \pm 1.07\%$. كشفت الصور المجهرية الإلكترونية عن الشكل الكروي للجسيمات النانوية. أظهر سلوك إطلاق الدواء نمطاً ثنائي الطور. وأدجت الصيغة المثلى للجسيمات النانوية في تركيبات مختلفة من هلام الكربوبول. وكان الأس الهيدروجيني للتركيبات المعدة في نطاق الأس الهيدروجيني لتجويف الفم الذي يتراوح بين $6.2 - 7.6$. أشار التحليل الإحصائي إلى أن تركيز الكاربوبول أثر بشكل كبير على اللزوجة والقدرة على التوزيع والالتصاق. وتمت مقارنة خصائص التركيبات المعدة بمنتج تجاري قائم على كين كير (Kin Care) كمرجع. تم اختيار كربوبول بوليمر بقوة 1% كعامل أمثل للهلام النانوي AA-PLGA. أظهرت جميع المواد الهلامية سلوكاً زائفاً مرغوباً لأنها تسهل تدفق الهلام من الأنبوب وقدرة على تكوين هلام لزج في موقع التطبيق. ومن ثم، فهو مرشح جيد للتطبيق الموضوعي على المخاط الشفوي. تم اختبار تركيبة الجسيمات النانوية المحسنة للتأثير السام للخلايا على خط خلايا OSCC. ساهمت الجزيئات النانوية AA-PLGA في تخفيض كبير في قدرة الخلايا السرطانية على البقاء بطريقة تعتمد على الجرعة وتبلغ قيمتها IC_{50} من 2420 ميكروغرام/مل. وكشفت نتائج هذه الدراسة عن إمكانية وجود هلام النانو AA-PLGA لعلاج OSCC وفتح طريق جديد لعلاج OSCC.

APPROVAL PAGE

I certify that I have supervised and read this study and that in my opinion, it conforms to acceptable standards of scholarly presentation and is fully adequate, in scope and quality, as a thesis for the degree of Master of Science in Pharmacy.



.....
Muhammad Salahuddin Haris
Supervisor

.....
Ahmad Fahmi bin Harun @ Ismail
Co-Supervisor

I certify that I have read this study and that in my opinion it conforms to acceptable standards of scholarly presentation and is fully adequate, in scope and quality, as a thesis for the degree of Master of Science in Pharmacy.

.....
Juliana Md Jaffri
Internal examiner

.....
Mohd Hanif Zulfakar
External examiner

This dissertation was submitted to the Department of Pharmaceutical Technology and is accepted as a fulfilment of the requirement for the degree of Master of Science in Pharmacy.

.....
Hazrina Ab. Hadi
Head, Department of Pharmaceutical
Technology

This thesis was submitted to the Kulliyyah of Pharmacy and is accepted as a fulfilment of the requirement for the degree of Master of Science in Pharmacy.

.....
Juliana Md Jaffri
Dean, Kulliyyah of Pharmacy

DECLARATION

I hereby declare that this thesis is the result of my own investigations, except where otherwise stated. I also declare that it has not been previously or concurrently submitted as a whole for any other degrees at IIUM or other institutions.

Nurul Ain binti Mohammad Hamdi



Signature

Date

INTERNATIONAL ISLAMIC UNIVERSITY MALAYSIA

**DECLARATION OF COPYRIGHT AND AFFIRMATION OF FAIR
USE OF UNPUBLISHED RESEARCH**

**ASCORBIC ACID LOADED PLGA NANOPARTICLES GEL AS
POTENTIAL ORAL SQUAMOUS CELL CARCINOMA SITE-
SPECIFIC TREATMENT**

I declare that the copyright holders of this thesis are jointly owned by the student and IIUM.

Copyright © 2021 Nurul Ain binti Mohammad Hamdi and International Islamic University Malaysia.
All rights reserved.

No part of this unpublished research may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, recording or otherwise without prior written permission of the copyright holder except as provided below.

1. Any material contained in or derived from this unpublished research may be used by others in their writing with due acknowledgement.
2. IIUM or its library will have the right to make and transmit copies (print or electronic) for institutional and academic purpose.
3. The IIUM library will have the right to make, store in a retrieved system and supply copies of this unpublished research if requested by other universities and research libraries.

By signing this form, I acknowledged that I have read and understand the IIUM Intellectual Property Right and Commercialization policy.

Affirmed by Nurul Ain binti Mohammad Hamdi



.....
Signature

.....
Date

ACKNOWLEDGEMENTS

All thanks and praises to Allah, The Almighty, whose Grace and Mercies have been with me throughout my master study. Without His Will, I would not be able to complete my thesis successfully.

First and foremost, I would like to thank my supervisor Asst. Prof. Dr. Muhammad Salahuddin Haris and Co-supervisor Asst. Prof. Dr Ahmad Fahmi Harun for the guidance, knowledge and continuous support throughout this programme.

I would also like to thank my family for always supporting me, encouraging me and being there for me.

I would like to convey my appreciation to Asst. Prof. Dr Izzat Fahimuddin Mohamed Sufian kindly giving me a flask of oral cancer cells (SCC-25). I would also like to thank Assoc. Prof. Dr Widya Lestari for teaching me cell culture experiments and MTT assays.

My thanks to all my colleagues, Sr. Nora, Sr. Shak, Sr. Putri, Sr. Akilah, Sr. Wani, Sr. May, Br. Rashid, all postgraduate students, all PG office members and Pharmaceutical Technology Department members for the valuable advice, support and assistance during the whole period of my study.

TABLE OF CONTENTS

Abstract	ii
Abstract in Arabic	iii
Approval Page.....	iv
Declaration	v
Copyright	vi
Acknowledgements	vii
List of Tables	xii
List of Figures	xiv
List of Abbreviations	xvii
CHAPTER ONE: INTRODUCTION	1
1.1 Background of the Study	1
1.2 Problem Statement.....	3
1.3 Literature Review	5
1.3.1 Oral Cancer	5
1.3.2 Treatment of OSCC and Its Challenges	7
1.3.3 Ascorbic Acid and Its Role in Cancer.....	9
1.3.3.1 Pro-oxidant Activity	11
1.3.3.2 Epigenetic Mechanism	12
1.3.3.3 Downregulation of Hypoxia-Inducible Factors (HIF-1 α)	12
1.3.4 Nanotechnology and Nanomedicine in Cancer Treatment	15
1.3.5 PLGA-Based Nanoparticles in Cancer Treatment	18
1.3.5.1 Double Emulsion Solvent Evaporation Technique	18
1.3.6 Local Delivery in OSCC	21
1.3.7 Carbopol [®] as Oral Gel.....	22
1.3.8 Analytical Method Validation (AMV).....	25
1.4 Research Objectives.....	28
1.4.1 General Objective.....	28
1.4.2 Specific Objectives.....	28
1.5 Research Flow	29
CHAPTER TWO: UV – VISIBLE SPECTROPHOTOMETRIC ANALYTICAL METHOD VALIDATION FOR AA-PLGA NANOPARTICLES QUANTIFICATION.....	30
2.1 Introduction.....	30
2.2 Materials	31
2.3 Methods	31
2.3.1 Preparation of Working Standard Solutions	31
2.3.2 Determination of Wavelength of Maximum Absorbance (λ max) ..	31
2.3.3 Preparation of Calibration Curve	32
2.3.4 Method Validation	32
2.3.4.1 Specificity.....	32
2.3.4.2 Linearity and Standard Curve.....	32
2.3.4.3 Accuracy.....	33

2.3.4.4 Intermediate Precision	33
2.3.4.5 LOD and LOQ	33
2.3.4.6 Robustness	34
2.4 Results and Discussion	34
2.4.1 Specificity	36
2.4.2 Preparation of Calibration Curve	37
2.4.3 Linearity and Standard Curve	39
2.4.4 Accuracy	40
2.4.5 Precision	41
2.4.6 LOD and LOQ	44
2.4.7 Robustness	44
2.5 Conclusion	47

CHAPTER THREE: FABRICATION AND CHARACTERISATION OF OPTIMISED AA-PLGA NANOPARTICLES..... 48

3.1 Introduction.....	48
3.2 Materials	49
3.3 Methods	50
3.3.1 Formulation of PLGA Nanoparticles	50
3.3.1.1 Preparation of PLGA Nanoparticles.....	50
3.3.1.2 Experimental Design and Analysis	53
3.3.2 Characterisation of AA-PLGA Nanoparticles	55
3.3.2.1 Measurement of Particle Size, PDI and Zeta Potential	55
3.3.2.2 Determination of Encapsulation Efficiency	55
3.3.2.3 ATR-FTIR	56
3.3.2.4 Scanning Electron Microscopic (SEM) Analysis.....	56
3.3.2.5 In Vitro Release Profile of the Fabricated Nanoparticles.....	57
3.3.3 Statistical Analysis	57
3.4 Results and Discussion	58
3.4.1 Statistical Analysis of Experimental Data.....	58
3.4.1.1 Effect on Particle Size	64
3.4.1.2 Effect on PDI.....	68
3.4.1.3 Effect on Encapsulation Efficiency	71
3.4.2 Nanoformulation Optimisation and Characterisation	73
3.4.2.1 Particle Size of the Optimised Nanoparticle	75
3.4.2.2 PDI of Optimised Nanoparticle	77
3.4.2.3 Zeta Potential of Optimised Nanoparticle	79
3.4.2.4 ATR-FTIR	83
3.4.2.5 Surface Morphology	85
3.4.2.6 In Vitro Drug Release From the PLGA Nanoparticles	87
3.5 Conclusion	89

CHAPTER FOUR: FORMULATION AND CHARACTERISATION OF AA-PLGA NANOPARTICLES INCORPORATED IN CARBOPOL® ORAL GEL 90

4.1 Introduction.....	90
4.2 Materials	93
4.3.1 Preparation of AA-PLGA Nanoparticles Carbopol® Gel	93
4.3.2 Characterisation of the Formulated Oral Gel	94
4.3.2.1 Physical Appearance of Gel Formulations	94

4.3.2.2 pH Determination	94
4.3.2.3 Determination of Viscosity.....	95
4.3.2.4 Measurement of Gel Rheology.....	95
4.3.2.5 Spreadability Test.....	96
4.3.2.6 Adhesion Study	96
4.3.2.7 In Vitro Drug Release.....	96
4.3.2.8 In Vitro Drug Release Kinetic	97
4.3.3 Statistical Analysis	97
4.4 Results and Discussion	98
4.4.1 Physical Appearance	98
4.4.2 pH.....	100
4.4.3 Viscosity.....	101
4.4.4 Flow Behaviour	103
4.4.5 Spreadability	105
4.4.6 Adhesion	107
4.4.7 In Vitro Release.....	110
4.4.8 In Vitro Drug Release Kinetic.....	112
4.5 Conclusion	113

CHAPTER FIVE: EVALUATION OF CYTOTOXICITY EFFECTS OF AA-PLGA NANOPARTICLES TOWARDS OSCC 114

5.1 Introduction.....	114
5.2 Materials	116
5.3 Method.....	116
5.3.1 Establishing Monolayer Cell Culture.....	116
5.3.1.1 Aseptic Technique	116
5.3.1.2 Cell Lines.....	117
5.3.1.3 Thawing of Frozen Cell Lines From Cryovials.....	117
5.3.1.4 Changing Media of Cell Line	117
5.3.1.5 Sub-Culturing of Cell Lines	118
5.3.1.6 Cryopreservation of Cell Lines	118
5.3.1.7 Cell Counting.....	119
5.3.1.8 Cell Seeding for Treatment	120
5.3.2 Preparation of Stock Solution	120
5.3.2.1 Preparation of Ascorbic Acid	121
5.3.2.2 Preparation of Empty PLGA Nanoparticles	121
5.3.2.3 Preparation of AA-PLGA Nanoparticles.....	122
5.3.2.4 Preparation of MTT Stock Solution	122
5.3.3 Cytotoxicity Evaluation of Empty PLGA Nanoparticles.....	122
5.3.4 Cytotoxicity Evaluation of Free Ascorbic Acid.....	123
5.3.5 Cytotoxicity Evaluation of AA-PLGA Nanoparticles	124
5.3.6 Morphological Changes	125
5.3.7 Statistical Analysis	125
5.4 Results and Discussion	125
5.4.1 SCC-25 Cell Line.....	125
5.4.2 Cytotoxicity Evaluation of Empty PLGA Nanoparticles.....	126
5.4.3 Cytotoxicity Evaluation of Ascorbic Acid.....	128
5.4.4 Cytotoxicity Evaluation of AA-PLGA Nanoparticles	132
5.4.5 Cell Morphological Changes of SCC-25 Cell Line	135
5.5 Conclusion	139

CHAPTER SIX: GENERAL DISCUSSION AND CONCLUSION	140
6.1 General Discussion	140
6.2 General Conclusion	144
6.3 Recommendation and Future Works	144
REFERENCES.....	146
APPENDIX I: CALCULATION OF ENCAPSULATION EFFICIENCY	168
APPENDIX II: CALCULATION OF IC₅₀.....	169
APPENDIX III: RESEARCH ACHIEVEMENT	170
APPENDIX IV: BIODATA OF THE STUDENT.....	171

LIST OF TABLES

Table 1.1	Problems and Solutions of This Study	4
Table 1.2	Anticancer Agents Used in the Treatment of Oral Cancer	9
Table 1.3	Summary of the Ascorbic Acid-Mediated Cytotoxic Effect in Cancer Cells	14
Table 1.4	Types of Nanoparticles That Commonly Studied in Oral Cancer Treatment	17
Table 1.5	The Characteristics of Optimised PLGA Nanoparticles That Are Successfully Formulated in Recent Studies	21
Table 1.6	The Validation Parameter and Its Definition	26
Table 1.7	Analytical Parameters Need to be Validated as per ICH Q2 (R1)	27
Table 2.1	Results of Calibration Curve at 266 nm	38
Table 2.2	Accuracy Data of the UV-visible Method for Ascorbic Acid. The Accepted Range is 98% to 102%	40
Table 2.3	Intraday Precision Data of the UV-visible Method for Ascorbic Acid. The Accepted Range is 98% to 102%	42
Table 2.4	Intraday Precision Data of the UV-visible Method for Ascorbic Acid. The Accepted Range is 98% to 102%.	43
Table 2.5	LOD and LOQ Data of the UV-visible Method for Ascorbic Acid	44
Table 2.6	The Correlation Coefficient R^2 Values and the Linear Equation for Robustness Study	45
Table 2.7	Validation Parameters Report	46
Table 3.1	Constant Parameters Applied for the Formulation of AA-PLGA Nanoparticles	51
Table 3.2	Process and Formulation Parameter of the Multilevel Categorical Full Factorial	53
Table 3.3	Outline of the Experimental Design and Results	54

Table 3.4	Descriptive Statistics of the Fitted Linear Model of Particle Size, PDI and Encapsulation Efficiency	60
Table 3.5	Result of Analysis of Variance (ANOVA) for Particle Size, PDI and Encapsulation Efficiency	61
Table 3.6	Optimal Formulation Parameters for the AA-PLGA Nanoparticles	73
Table 3.7	Solutions for 12 Combinations of Categorical Factor Levels	74
Table 3.8	Validation of the Model by Comparing the Predicted Value with the Observed Experimental Value	75
Table 4.1	Composition of the Carbopol® Gel Formulation	94
Table 4.2	Physical Appearance of AA-PLGA Nanoparticles Oral Gel	98
Table 4.3	Apparent Viscosity of the Formulated Gel at the Shear Rate Of 100 s ⁻¹	103
Table 4.4	Rheological Profiles of the Formulated Gel	104
Table 4.5	Spreadability of the Formulated Gels and Commercial Product	106
Table 4.6	The Result of the Adhesion Test	108
Table 4.7	In Vitro Release Kinetic Study of Topical AA-PLGA Oral Gel with 1% Carbopol® 940	112

LIST OF FIGURES

Figure 1.1	Research Flow	29
Figure 2.1	Chemical Structure of Ascorbic Acid	35
Figure 2.2	UV–visible Spectra of Ascorbic Acid	36
Figure 2.3	The Wavelength Scanning Spectrum of Ascorbic Acid and Distilled Water for Specificity	37
Figure 2.4	The Standard Curve of Ascorbic acid Constructed for Linearity Study	39
Figure 3.1	Steps of Ascorbic Acid-PLGA Nanoparticles Preparation via a Double Emulsion Solvent Evaporation Method	52
Figure 3.2	Graphical Plots of the Experimental Values Versus the Model Predicted Values for (a) Particle Size, (b) PDI, (c) Encapsulation Efficiency	62-63
Figure 3.3	3D Graph of Particle Size Model	67
Figure 3.4	3D Graph of the PDI Model	70
Figure 3.5	3D Graph of Encapsulation Efficiency Model	72
Figure 3.6	The Z-Average Particle Size (252.0 nm) and PDI (0.151) of The Optimised Nanoparticles Determined by Zeta Sizer	78
Figure 3.7	The Zeta Potential of the Optimised AA-PLGA Nanoparticles	81
Figure 3.8	Illustration of Negatively Charged Ascorbic Acid – PLGA Nanoparticles Repel Each Other in the Dispersion System	82
Figure 3.9	ATR-FTIR Spectrum of a) Free Ascorbic Acid Powder, b) Empty PLGA and c) AA-PLGA Nanoparticles	84
Figure 3.10	SEM Image of the Freeze-Dried Optimised AA-PLGA Nanoparticles. Red Circles Indicate the Spherical-Shaped Nanoparticles	8
Figure 3.11	In Vitro Release of Ascorbic Acid from PLGA Nanoparticles in PBS (Ph 7.4) At 37°C. Results Are Given as Mean (n=3)	88

Figure 4.1	Graphical Abstract of Chapter 4	92
Figure 4.2	The Physical Appearance of Blank Gel and Ascorbic Acid-PLGA Nanoparticles Gel with Different Concentrations of Carbopol [®] 940	99
Figure 4.3	Gel pH	100
Figure 4.4	Rheological Profiles of the Formulated Gel	105
Figure 4.5	Illustration of the Mucoadhesive Effect of Carbopol [®] 940 Polymer with Oligosaccharides of the Mucous Membrane	109
Figure 4.6	In Vitro Release Profile of Encapsulated Ascorbic Acid from 1% Carbopol [®] Oral Gel at pH 7	111
Figure 5.1	Graphical Abstract of Chapter 5	115
Figure 5.2	Microscopic Features of OSCC Cell Line (SCC-25). The Image Was Taken at a Magnification of 10X	126
Figure 5.3	Cell Viability Percentage of SCC-25 Cell Line After Treatment with Blank PLGA for 24 Hours and 48 Hours. Data Presented as Mean \pm SD. NS (p-value > 0.05) Indicates No Significant Difference Between the Control and Treated Groups	128
Figure 5.4	Cell Viability Percentage of SCC-25 Cell Line After Treatment with Ascorbic Acid for 24 Hours. Data Presented as Mean \pm SD. *p-value < 0.05 Indicates a Significant Difference	129
Figure 5.5	Cell Viability Percentage of SCC-25 Cell Line After Treatment with Ascorbic Acid for 24 Hours And 48 Hours. Data Presented as Mean \pm SD. *p-value < 0.05 Indicates a Significant Difference	130
Figure 5.6	Cell Viability Percentage of SCC-25 Cell Line After Treatment With AA-PLGA Nanoparticles for 24 Hours. Data Presented as Mean \pm SD. *p-value < 0.05 And **p-value < 0.001 Indicate a Significant Difference Between Control (Untreated) and Treated Group	133
Figure 5.7	Microscopic Appearance of SCC-25 Oral Cancer Cell Line After Treatment With 600 μ g/mL of Ascorbic Acid for 24 Hours and 48 Hours: (A) Untreated SCC 25 Cell Line, (B) SCC 25 Cell Line Incubated with 600 μ g/mL of Ascorbic Acid for 24 Hours, (C) SCC 25 Cell Line Incubated with 600 μ g/mL of Ascorbic Acid for 48 Hours. The Red Circles	

Showed Severe Morphological Alteration Which Indicated the Cell Death. The Images Were Taken at a Magnification Of 10X

137

Figure 5.8 Microscopic Appearance of SCC-25 Cell Line: (A) Untreated SCC-25 Cell Line and (B) SCC-25 Cell Line Incubated with 1000 $\mu\text{g}/\text{mL}$ of AA-PLGA Nanoparticles. The Red Circles Showed Severe Morphological Alteration Which Indicated the Cell Death. The Images Were Taken at a Magnification of 10X

138

LIST OF ABBREVIATIONS

AA-PLGA	Ascorbic acid loaded PLGA
OSCC	Oral squamous cell carcinoma
HPV	Human papillomavirus
SVCT	Sodium-dependent vitamin C transporters
5-hmC	5-hydroxymethylcytosine
TET	Ten-eleven-translocation
PLGA	Poly lactic-co-glycolic acid
PDI	Polydispersity index
UV	Ultraviolet
SD	Standard deviation
LOD	Limit of detection
LOQ	Limit of quantification
PVA	Polyvinyl alcohol
PBS	Phosphate buffer solution
ATR-FTIR	Attenuated total reflectance-fourier transform infrared spectroscopy
ANOVA	Analysis of variance
CGM	Complete growth media
ROS	Reactive oxygen species
DMSO	Dimethyl sulfoxide
TBEA	Trypan blue exclusion assay
GSH	Reduced glutathione
GSSG	Oxidised glutathione

MTT 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide

CHAPTER ONE

INTRODUCTION

1.1 BACKGROUND OF THE STUDY

Oral cancer accounts for 377, 713 new cases and 177, 757 death in 2020, making it the seventeenth most common cancer worldwide (Sung et al., 2021). Meanwhile, 742 new cases and 403 deaths were reported in Malaysia in 2020 (World Health Organization, 2021). It is associated with significant mortality, especially if the patient is diagnosed at an advanced stage (Carolina et al., 2017). Though oral cancer was not among the top 10 cancers in Malaysia, it is still a major concern because two-third of the cases reported are diagnosed at a late stage (Ghani, Razak, et al., 2019). According to Yaaqob et al., (2019), the oral cancer stage was statistically important, with patients in the late stage (stage III and stage IV) having a five times greater chance of dying compared to those in early-stage (stage I and stage II). Furthermore, Malaysians had a poorer 5-year survival rate of 40.9% compared to the world 5-year survival rate of roughly 50%. (Ghani, Razak, et al., 2019). Often, chemotherapy is required in the late-stage as well as in the metastatic oral cancer (Hartner, 2018). Cisplatin and fluorouracil, both available in intravenous injection, are known as the most commonly used anticancer agents in oral cancer (Ketabat et al., 2019). Various detrimental adverse effects due to systemic conventional chemotherapy approach have been reported and remain the major concern to the patients (Marcazzan et al., 2018). For example, cisplatin is associated with three distinct adverse effects, which are renal toxicity, neurotoxicity, and gastrointestinal toxicity (Aldossary, 2019). Besides, chemoresistance developed worldwide in various cancer, including OSCC and was recognised as the primary source

of treatment failure (S. Li et al., 2018). Cisplatin resistance has been reported where more than 30% of patients acquired resistance to cisplatin during early treatment administration. Meanwhile, the others slowly develop resistance after several rounds of chemotherapy (Zhuang et al., 2017). Hence, a new innovative and safer alternative for oral cancer therapy is highly in need.

The pharmacological ascorbic acid dose, which is administered intravenously, has been proven as a promising anticancer agent in both in vivo and in vitro studies (Vissers & Das, 2018). Its cytotoxicity effect against cancer cells has been exhibited in various cell lines, including oral cancer cell lines (Baek et al., 2017; Ohwada et al., 2017; Zhou et al., 2020). However, the instability of ascorbic acid in a bulk aqueous system was regarded as a challenge for its formulation. In certain conditions such as exposure to air and light, ascorbic acid undergoes reversible oxidative degradation to dehydroascorbic acid. Dehydroascorbic acid can further be hydrolysed irreversibly to an inactive compound called 2,3-diketogulonic acid (Sheraz et al., 2015). Nevertheless, the application of nanotechnology particularly encapsulating ascorbic acid in nanoparticles has been shown to preserve its stability and enhance the delivery in a sustained release manner (Duarah et al., 2017). Topical, localised, and non-invasive approach are favourable strategies for oral cancer treatment (Ferreira et al., 2020). Apart from that, easy access to the affected area has made local intraoral drug delivery an attractive route for the delivery of chemotherapeutic agents (Matos et al., 2020). Nonetheless, environmental factor particularly continuous saliva secretion should come into consideration in developing a suitable formulation for oral cavity application. This normal physiologic phenomenon would dilute and remove the drug from the target site (Desai, 2018). Thus, the incorporation of the mucoadhesive polymer is necessary to

overcome this issue by interacting with the mucous glycoprotein of the oral mucosa (Netsomboon & Bernkop-Schnürch, 2016; Sarma et al., 2019).

Therefore, this study aims to formulate optimised ascorbic acid loaded polymeric nanoparticles intended to treat oral cancer. The formulated nanoparticles were further incorporated into a mucoadhesive polymer, specifically Carbopol[®] as an oral gel for topical and controlled release delivery of ascorbic acid to the tumour site with better residence time. The formulation was tested for the cytotoxicity activity against an OSCC cell line by using an MTT assay.

1.2 PROBLEM STATEMENT

As far as this is concerned, conventional chemotherapy approach is associated with several disadvantages particularly terrible adverse effects to the patient and occurrence of chemoresistance towards commonly used chemotherapy which accounts for the treatment failure, disease recurrence and metastasis (S. Li et al., 2018; Marcazzan et al., 2018; Zhuang et al., 2017). Thus, identifying a new potential anticancer agent and developing a safe, effective and non-invasive drug delivery is necessary for complementary or alternative treatment of OSCC. A high dose of ascorbic acid has been shown to be cytotoxic against a variety of cancer lines, including OSCC (Baek et al., 2017; Ohwada et al., 2017; Zhou et al., 2020). Topical administration of high dose ascorbic acid directly to cancerous site is favourable due to the non-invasive and straightforward approach. However, formulating ascorbic acid is difficult due to its instability in the bulk aqueous system (Sheraz et al., 2015). Several approaches have been adopted to preserve its stability and enhance its delivery to the target site such as formulation of multiple emulsion, microparticles including nanoparticles (Duarah et al., 2017; Kheynoor et al., 2018; Sheraz et al., 2015). Besides, salivary washout also is the

challenge to retain the potential anticancer agent longer to the targeted site (Desai, 2018). However, the application of the mucoadhesive agent reported prolonging drug residence time (Kassab et al., 2017). Table 1.1 summarises problems and solutions of this study.

Table 1.1 Problems and solutions of this study

Problems	Solutions
Dreadful adverse effects and chemoresistance reported in oral cancer due to the conventional chemotherapy approach impair the effectiveness of cancer treatment (Li et al., 2018).	Identify a new potential anticancer agent namely ascorbic acid (Baek et al., 2017; Ohwada et al., 2017; Zhou et al., 2020).
Formulating ascorbic acid is difficult due to its instability in the bulk aqueous system (Sheraz et al., 2015).	Formulation of nanoparticles (Duarah et al., 2017; Kheynoor et al., 2018).
Salivary washout and low drug retention are the major hindrance associated with topical delivery of the drug directly in the oral cavity (Desai, 2018).	Application of mucoadhesive polymer namely Carbopol [®] as oral gel (Desai, 2018).

1.3 LITERATURE REVIEW

1.3.1 Oral Cancer

Oral cancer is a malignant tumour that develops on the lips or in the oral cavity such as the tongue, cheeks, floor of the mouth, hard and soft palate (Hinaz & Geetha, 2018). The term oral cancer is frequently used interchangeably with oral squamous cell carcinoma (OSCC) since more than 90% of malignant tumour developed in the oral cavity represented by OSCC (Gunjal et al., 2020). OSCC is explained as an invasive abnormal growth of epithelial cells with variable levels of squamous differentiation derived from stratified squamous epithelium of the oral mucosa (Suciu et al., 2014). The clinical presentation of oral cancer is broad (Wong & Wiesenfeld, 2018). Non-healing ulcer, white lesion, red patches, uncontrolled growth of oral mucosa, lymph node enlargement, mobile teeth, tooth pain, orofacial pain and mouth bleeding are the distinct signs and symptoms of oral cancer (Muthu et al., 2018). Lip and oral cavity cancer account for 377, 713 new cases and 177, 757 death in 2020, putting it the seventeenth most common cancer worldwide (Sung et al., 2021). The prevalence of oral cancer differs greatly depending on the geographical region where it is being diagnosed. Globally, the majority of the highest rate of oral cancer incidence is concentrated in South Asia, Central Asia and Oceania. South Asian countries such as India and Sri Lanka possess the highest incidence of oral cancer cases (Miranda-Filho & Bray, 2020).

Oral cancer creates a massive burden on public health. It is associated with a dismal prognosis especially if the patient is diagnosed at a late stage (Parkinson, 2018). Almost 86% of oral cancers are diagnosed at an advanced stage (Haron et al., 2020). Though oral cancer was not among the top 10 cancer in Malaysia, it is still a major concern since two-third of the cases reported are diagnosed at a late stage (Chou et al., 2019). Limited access to specialists and lack of awareness of oral cancer and its

alarming signs and symptoms are the contributing factors related to late diagnosis (Ghani, Razak, et al., 2019; Haron et al., 2020). Moreover, the 5-year survival rate of oral cancer of the Malaysian population is 40.9% lower than the global survival rate which is around 50% (Ghani, Ramanathan, et al., 2019). The recurrence and metastasis of oral cancer continue to happen after the 5-year survival yet with a reduced rate (Chou et al., 2019).

The occurrence of oral cancer is strongly related to exposure to the risk factors such as tobacco smoking, alcohol consumption, betel nut chewing and human papillomavirus (HPV). Indeed, frequent exposure to multiple risk factors produces a higher probability of developing oral cancer. For instance, practising multiple risks concurrently such as smoking, drinking alcohol and chewing betel nuts exhibited the highest risk for developing oral cancer (Ghani, Razak, et al., 2019). Besides, habit of risks practised in Malaysia significantly correlated with the ethnicity. Smoking alone is the most common habit practised by Malays. Smoking and drinking alcohol are common in Chinese meanwhile quid chewing is common in Indians (Ghani, Razak, et al., 2019).

Interestingly, the anatomical location and clinical characteristic of oral cancer are correlated to the risk factors practised. Those smoking and drinking alcohol reported more endophytic tumour and frequently developed on the lateral border of the tongue and mouth floor. Meanwhile, those practising chewing betel quid which is usually held in the buccal sulcus would develop an exophytic tumour on the gingiva, buccal sulcus and buccal mucosa (Warnakulasuriya, 2009). This finding is consistent with a study conducted on the Malaysian population. Tongue and floor of the mouth is the most common tumour site in Malays and Chinese. Meanwhile, buccal mucosa and gingiva are the common locations for Indians and Indigenous people (Ghani, Razak, et al., 2019)